CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

Phase 1

Completed

Conditions: Pancreatic Neoplasms
Bile Duct Neoplasms

Interventions: Drug: Oxaliplatin
Drug: Capecitabine
Drug: Sorafenib

Registration Number: NCT00634751

Lead Sponsor: University of Wisconsin, Madison

Brief Summary: This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs approved by the Food and Drug Administration (FDA) for use in the treatment of different cancers. Their use in this exact combination is considered experimental for the treatment of pancreas and biliary tract; however the combination has been tested in a preliminary trial. We are also testing a survey designed. The purpose of this research study is to investigate the chemotherapy drug sorafenib in combination with oxaliplatin and capecitabine chemotherapies for the treatment of pancreas and biliary tract cancers.to help patients report their side effects from chemotherapy treatments.

Detailed Description: Primary Objectives

* To assess the overall safety of sorafenib when administered with "the 2DOC regimen" capecitabine and oxaliplatin in patients with advanced or metastatic pancreas or biliary tract cancers.

* To define the dose limiting toxicity and maximally tolerated dose of this combination.

* To assess the clinical response rate (stable, partial and complete responses) of the combination in patients with advanced or metastatic pancreas or biliary tract cancers.

Secondary Objectives

* To define the time to progression and overall survival for patients treated with this regimen.

* To evaluate the congruency of the Adverse Events Self-Report Survey in determining patient reported side effects of treatment

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 48

Inclusion Criteria

Patients must have histologically or cytologically confirmed locally advanced inoperable or metastatic adenocarcinoma of the pancreas or biliary tract who have not previously received more than one systemic treatment for their disease.
Age at least 18 years old
ECOG performance status 0-2.
Patients must have adequate organ and marrow function as defined below:
WBC at least 3,000
ANC at least 1,500
PLT at least 100,000
total bilirubin must be less than 2.5 x institutional upper limit of norm
AST(SGOT)/ALT(SGPT) must be less than 5 X institutional upper limit of normal
creatinine clearance must be greater than 50 mL/min as calculated by the Cockroft-Gault formula
Patients with ≤ grade 2 (CTC 3.0) neuropathy.
At least one measurable lesion as defined by RECIST criteria
The effects of oxaliplatin, capecitabine and sorafenib on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because DNA alkylating agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Because the risk of toxicity in nursing infants secondary to oxaliplatin treatment of the mother is unknown but may be harmful, breastfeeding should be discontinued if the mother is treated with oxaliplatin.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

No concomitant radiation therapy, or other systemic cancer therapies.
Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other toxicities.
History of allergy to platinum compounds, capecitabine, sorafenib or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy.
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months, symptomatic congestive heart failure, unstable angina pectoris within 3 months prior to entry study, myocardial infarction within 6 months prior to study entry, ongoing cardiac arrhythmia (excluding atrial fibrillation), uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 90 mmHg, despite optimal medical management), pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug, or any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug, serious non-healing wound, ulcer, or bone fracture, evidence or history of bleeding diathesis or coagulopathy.
Pregnant or nursing women are excluded from this study because oxaliplatin, capecitabine and sorafenib is a DNA alkylating agent with the potential for teratogenic or abortifacient effects. Female patients of reproductive potential must have a negative urine or serum pregnancy test within two weeks prior to enrolling.
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.
Because of drug interactions with sorafenib, use of St. John's Wort or rifampin (rifampicin) is contraindicated. Patients may discontinue the use of these drugs to become eligible for the study
Any condition that impairs patient's ability to swallow whole pills.
HIV-positive patients receiving anti-retroviral therapy (HAART) are excluded from the study because of possible pharmacokinetic interactions.
Second malignancy within the past 3 years (excluding nonmelanoma skin cancer and in situ cancers) that has not been treated with curative intent and is not currently without evidence of disease,
Patients with known gastrointestinal malabsorption syndromes are excluded as this concurrent illness will affect absorption of the oral medications.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Phase I: 200mg Sorafenib+2DOC	Oxaliplatin	Cohort 1: 200mg Sorafenib+2DOC Oxaliplatin + Oral Capecitabine + Sorafenib
Phase I: 400mg Sorafenib BID+2DOC	Oxaliplatin	Cohort 2: 400mg Sorafenib+2DOC Oxaliplatin + Oral Capecitabine + Sorafenib
Phase I: 200mg Sorafenib+2DOC	Capecitabine	Cohort 1: 200mg Sorafenib+2DOC Oxaliplatin + Oral Capecitabine + Sorafenib
Phase I: 200mg Sorafenib+2DOC	Sorafenib	Cohort 1: 200mg Sorafenib+2DOC Oxaliplatin + Oral Capecitabine + Sorafenib
Phase I: 400mg Sorafenib BID+2DOC	Capecitabine	Cohort 2: 400mg Sorafenib+2DOC Oxaliplatin + Oral Capecitabine + Sorafenib
Phase I: 400mg Sorafenib BID+2DOC	Sorafenib	Cohort 2: 400mg Sorafenib+2DOC Oxaliplatin + Oral Capecitabine + Sorafenib
Phase II: Pancreatic Cancer	Oxaliplatin	Oxaliplatin + Oral Capecitabine + Sorafeni
Phase II: Pancreatic Cancer	Capecitabine	Oxaliplatin + Oral Capecitabine + Sorafeni
Phase II: Pancreatic Cancer	Sorafenib	Oxaliplatin + Oral Capecitabine + Sorafeni
Phase II: Biliary Tract Cancer	Oxaliplatin	Oxaliplatin + Oral Capecitabine + Sorafeni
Phase II: Biliary Tract Cancer	Capecitabine	Oxaliplatin + Oral Capecitabine + Sorafeni
Phase II: Biliary Tract Cancer	Sorafenib	Oxaliplatin + Oral Capecitabine + Sorafeni

Primary Outcome Measures

Name	Time	Method
Overall Response Rate	Up to 18 months	Response rate of participant to treatment

Secondary Outcome Measures

Name	Time	Method
Progression-free Survival (PFS)	Up to 18 months	Time to progression, defined as number of days from day of first study drug administration to the day the patient experiences an event of disease progression or death; summarized using point estimates of the median time to progression and associated 95% confidence intervals for each stratum separately.
Overall Survival	Up to 18 months	Overall survival, defined as number of days from the day of first study drug administration to the day the patient dies, summarized using point estimates of the median time to progression, and associated 95% confidence intervals